Amylyx Appoints Chief Medical Officer and Global Head, Supply Chain
Amylyx Pharmaceuticals, a clinical-stage pharmaceutical company developing a novel therapeutic for ALS, Alzheimer’s disease and other neurodegenerative diseases, just appointed Dr. Patrick Yeramian as Chief Medical Officer and Tom Holmes as Global Head, Supply Chain.
Patrick Yeramian, MD, MBA
Chief Medical Officer
Dr. Yeramian joined Amylyx as Chief Medical Officer in March 2019 bringing to the company more than 30 years of pharmaceutical industry experience. He was previously the consulting medical director for Amylyx, where he has supported the pre-IND and IND filings of AMX0035 for the treatment of amyotrophic lateral sclerosis and Alzheimer’s disease, and has overseen the design and execution of both clinical trials.
Throughout his career Dr. Yeramian has supervised the clinical development of new drugs, biopharmaceuticals, cellular therapy agents and vaccines. He has held prominent roles in the approval of several drug (metronidazole – Flagyl MR®), biological (interferon alpha – Multiferon®, nafarelin – Synarel®) and device (Inerpan®) applications by the FDA and EMA and granting of more than 20 successful INDs and IMPDs. Previously he served as Chief Medical Officer at Viragen, Inc. where he was responsible for the development of global clinical and regulatory strategies and for the implementation of clinical programs worldwide. Earlier in his career, Dr. Yeramian served as Director of clinical research at GD Searle where he supervised the clinical programs for antibiotics, antivirals, sepsis/thrombosis and cancer vaccines. He also previously served as Medical Director of the Vaccine and Gene Therapy Institute in Florida.
Dr. Yeramian holds a Medical Degree from the University of Paris together with a Master of Clinical Science in experimental oncology and a Graduate Degree in molecular virology. He received his Master of Business Administration from Rutgers University. He completed his medical residency in oncology at the Saint-Louis Hospital in Paris.
Global Head, Supply Chain
Tom Holmes joined Amylyx in March 2019 as Global Head, Supply Chain, bringing more than 25 years of leadership experience in supply chain, biopharmaceutical manufacturing and program management. Prior to joining Amylyx, Tom was the Senior Director of External Manufacturing at Biogen Inc., a role he held for 10 years. As Senior Director, Tom managed Biogen’s global external manufacturing network and was responsible for driving supply contracting decisions for 11 commercial assets and more than 42 new molecular entities in various stages of clinical development. Tom held several positions at Biogen beginning in 1994 including planning, logistics program management, Launch Lead, and manufacturing. Tom received a Bachelor of Science in Business Administration with a concentration in Management from Salem State University.